Global Information
회사소개 | 문의 | 비교리스트

재발성 악성 신경교종 : 파이프라인 리뷰

Recurrent Malignant Glioma (Oncology) - Drugs in Development, 2021

리서치사 Global Markets Direct
발행일 2021년 12월 상품코드 247796
페이지 정보 영문 56 Pages 배송안내
가격
US $ 2,000 ₩ 2,574,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 5,149,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,723,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


재발성 악성 신경교종 : 파이프라인 리뷰 Recurrent Malignant Glioma (Oncology) - Drugs in Development, 2021
발행일 : 2021년 12월 페이지 정보 : 영문 56 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

재발성 악성 신경교종은 치료 후 종양의 재발로 정의됩니다. 치료에는 화학요법 및 방사선요법 등이 포함됩니다.

재발성 악성 신경교종(Recurrent Malignant Glioma) 치료제 개발 상황에 대해 조사분석했으며, 파이프라인 제품 개요, 임상시험 단계별 제품 개요, 주요 기업 개요, 치료제 개요, 파이프라인 제품의 최신 동향, 최신 뉴스와 프레스 릴리스 등에 대한 체계적인 정보를 정리하여 전해드립니다.

목차

서론

재발성 악성 신경교종 개요

치료제 개발

  • 파이프라인 제품 : 개요
  • 파이프라인 제품 : 비교 분석

개발중인 치료제 : 기업별

조사중 치료제 : 대학/연구기관별

파이프라인 제품 개요

  • 임상시험 단계 제품

개발중인 제품 : 기업별

조사중 제품 : 대학/연구기관별

치료제 개발 참여 기업

  • Amgen Inc.
  • AstraZeneca Plc
  • Eisai Inc.
  • MediGene AG
  • Tiziana Life Sciences Plc
  • ZIOPHARM Oncology, Inc.

치료제 평가

  • 단일요법(Monotherapy)
  • 표적별
  • 작용기전별
  • 투여 경로별
  • 분자 종류별

치료제 개요

  • Ad-RTS-IL-12
  • Carboxyamidotriazole Orotate
  • Cell Therapy for Refractory Gliomas
  • Cell Therapy to Target IL-13 for Malignant Glioma
  • Dendritic Cell Therapy for Oncology
  • Dendritic Cell Therapy for Recurrent Malignant Glioma
  • disufenton sodium
  • DNX-2401
  • G-207
  • irofulven
  • milciclib
  • rilotumumab

파이프라인 제품의 최신 동향

휴지 상태인 프로젝트

개발이 중지된 제품

제품 개발 마일스톤

  • 최신 뉴스와 프레스 릴리스

부록

도표

LSH 15.09.04

List of Tables

List of Tables

  • Number of Products under Development for Recurrent Malignant Glioma, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Recurrent Malignant Glioma - Pipeline by Candel Therapeutics Inc, 2021
  • Recurrent Malignant Glioma - Pipeline by Hebei Senlang Biotechnology Co Ltd, 2021
  • Recurrent Malignant Glioma - Pipeline by Immunomic Therapeutics Inc, 2021
  • Recurrent Malignant Glioma - Pipeline by InSight Biopharmaceuticals Ltd (Inactive), 2021
  • Recurrent Malignant Glioma - Pipeline by Oblato Inc, 2021
  • Recurrent Malignant Glioma - Pipeline by PharmAbcine Inc, 2021
  • Recurrent Malignant Glioma - Pipeline by Smerud Medical Research International AS, 2021
  • Recurrent Malignant Glioma - Pipeline by Stella Pharmaceuticals Pvt Ltd, 2021
  • Recurrent Malignant Glioma - Dormant Projects, 2021
  • Recurrent Malignant Glioma - Dormant Projects, 2021 (Contd..1)
  • Recurrent Malignant Glioma - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Recurrent Malignant Glioma, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Top 10 Routes of Administration, 2021
  • Number of Products by Stage and Top 10 Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Recurrent Malignant Glioma - Drugs In Development, 2021, provides an overview of the Recurrent Malignant Glioma (Oncology) pipeline landscape.

Recurrent malignant glioma is defined as recurrence of tumor after treatment. Symptoms include chest pain due to a tumor located in the chest area of the spinal cord, erectile dysfunction, lack of ability to feel changes in temperature, loss of muscle control, loss of bowel or bladder control, numbness or tingling, pain in the arm, neck, back, or leg caused by tumors in the neck area of the spinal cord and weakness in the limbs or upper body. Treatment includes chemotherapy and radiation therapy

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Recurrent Malignant Glioma - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Recurrent Malignant Glioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Recurrent Malignant Glioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Recurrent Malignant Glioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 4 and 2 respectively. Similarly, the Universities portfolio in Phase II and Phase I stages comprises 4 and 1 molecules, respectively.

Recurrent Malignant Glioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Recurrent Malignant Glioma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Recurrent Malignant Glioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Recurrent Malignant Glioma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Recurrent Malignant Glioma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Recurrent Malignant Glioma (Oncology)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Recurrent Malignant Glioma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Recurrent Malignant Glioma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Recurrent Malignant Glioma - Overview
  • Recurrent Malignant Glioma - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Recurrent Malignant Glioma - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Recurrent Malignant Glioma - Companies Involved in Therapeutics Development
  • Recurrent Malignant Glioma - Drug Profiles
  • Recurrent Malignant Glioma - Dormant Projects
  • Recurrent Malignant Glioma - Discontinued Products
  • Recurrent Malignant Glioma - Product Development Milestones
  • Featured News & Press Releases
  • Apr 21, 2017: Japan's Ministry of Health, Labour and Welfare Announces SAKIGAKE Designation For Stella Pharma's Cancer Drug
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q